Fresenius Medical Care AG & Co. KGaA (FMEA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fresenius Medical Care AG & Co. KGaA (FMEA) has a cash flow conversion efficiency ratio of 0.070x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.00 Billion ≈ $1.17 Billion USD) by net assets (€14.28 Billion ≈ $16.70 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Fresenius Medical Care AG & Co. KGaA - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Fresenius Medical Care AG & Co. KGaA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Fresenius Medical Care AG & Co. KGaA carry for a breakdown of total debt and financial obligations.
Fresenius Medical Care AG & Co. KGaA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fresenius Medical Care AG & Co. KGaA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GAIL (India) Limited
NSE:GAIL
|
0.065x |
|
CENTRICA ADR NEW 2004/4
F:CENN
|
N/A |
|
Guangxi Guiguan Electric Power Co Ltd
SHG:600236
|
0.114x |
|
NortonLifeLock Inc
F:SYM
|
0.047x |
|
China Aerospace Times Electronics Co Ltd
SHG:600879
|
0.006x |
|
Solventum Corp.
NYSE:SOLV
|
0.015x |
|
Hyundai Glovis
KO:086280
|
0.021x |
|
Chongqing Changan Automobile Co Ltd
SHE:000625
|
0.129x |
Annual Cash Flow Conversion Efficiency for Fresenius Medical Care AG & Co. KGaA (2016–2025)
The table below shows the annual cash flow conversion efficiency of Fresenius Medical Care AG & Co. KGaA from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Fresenius Medical Care AG & Co. KGaA stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €14.28 Billion ≈ $16.70 Billion |
€2.68 Billion ≈ $3.13 Billion |
0.188x | +24.04% |
| 2024-12-31 | €15.77 Billion ≈ $18.44 Billion |
€2.39 Billion ≈ $2.79 Billion |
0.151x | -14.65% |
| 2023-12-31 | €14.83 Billion ≈ $17.33 Billion |
€2.63 Billion ≈ $3.07 Billion |
0.177x | +26.38% |
| 2022-12-31 | €15.45 Billion ≈ $18.06 Billion |
€2.17 Billion ≈ $2.53 Billion |
0.140x | -21.22% |
| 2021-12-31 | €13.98 Billion ≈ $16.34 Billion |
€2.49 Billion ≈ $2.91 Billion |
0.178x | -48.12% |
| 2020-12-31 | €12.33 Billion ≈ $14.42 Billion |
€4.23 Billion ≈ $4.95 Billion |
0.343x | +76.89% |
| 2019-12-31 | €13.23 Billion ≈ $15.46 Billion |
€2.57 Billion ≈ $3.00 Billion |
0.194x | +21.43% |
| 2018-12-31 | €12.90 Billion ≈ $15.08 Billion |
€2.06 Billion ≈ $2.41 Billion |
0.160x | -21.05% |
| 2017-12-31 | €10.83 Billion ≈ $12.66 Billion |
€2.19 Billion ≈ $2.56 Billion |
0.202x | +14.14% |
| 2016-12-31 | €10.89 Billion ≈ $12.74 Billion |
€1.93 Billion ≈ $2.26 Billion |
0.177x | -- |
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arr… Read more